Risk compensation: The Achilles' heel of innovations in HIV prevention?

BMJ

Volumn 332, Issue 7541, 2006, Pages 605-

  Cassell, michael M ^a   Halperin, Daniel T ^b   Shelton, James D ^b   Stanton, David ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b UNITED STATES AGENCY FOR INTERNATIONAL DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; MICROBICIDE; TENOFOVIR; VACCINE;

CIRCUMCISION; CONDOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NOTE; PRIORITY JOURNAL; RISK ASSESSMENT; HIGH RISK BEHAVIOR; MASS COMMUNICATION; PSYCHOLOGICAL ASPECT; REVIEW; UNSAFE SEX;

DIFFUSION OF INNOVATION; HIV INFECTIONS; HUMANS; RISK ASSESSMENT; RISK-TAKING; UNSAFE SEX;

EID: 33644957630     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.332.7541.605     Document Type: Article

References (24)

1. Auvert B, Taljaard D, Lagarde E, Tambekou-Sobngwi J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 trial. PLoS Med 2005; 2 (11): 1–11.
2. Weiss HA, Quigley MA, Hayes RJ. Male circumcision and risk of HIV infection in sub-Saharan Africa: a systematic review and meta-analysis. AIDS 2000; 14: 2361–2370.
3. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 2000; 342: 921–929.
4. Hearst N, Chen S. Condom promotion for AIDS prevention in the developing world: is it working? Stud Fam Plann 2004; 35: 39–47.
5. Foss AM, Vickerman PT, Heise L, Watts CH. Shifts in condom use following microbicide introduction: should we be concerned? AIDS 2003; 17: 1227–1237.
6. Gray RH, Li X, Wawer MJ, Gange SJ, Serwadda D, Sewankambo NK. Stochastic simulation of the impact of antiretroviral therapy and HIV vaccines on HIV transmission; Rakai, Uganda. AIDS 2003; 17: 1941–1951.
7. Blower SM, Ma L, Farmer P, Koenig S. Predicting the impact of antiretrovirals in resource poor settings: preventing HIV infections whilst controlling drug resistance. Curr Drug Targets Infect Disord 2003; 3: 345–353.
8. Wilson D. Partner reduction and the prevention of HIV/AIDS: the most effective strategies come from communities. BMJ 2004; 328: 848–849.
9. Allen T, Heald S. HIV/AIDS policy in Africa: What has worked in Uganda and what has failed in Botswana? J Int Dev 2004; 16: 1141–1154.
10. Green EC. Rethinking AIDS prevention. Westport, CT: Praeger, 2003.
11. Richens J, Imrie J, Copas A. Condoms and seat belts: the parallels and the lessons. Lancet 2000; 355: 400–403.
12. Autier P, Dore J, Cattaruzza MS, Renard F, Luther H, Gentiloni-Silverj F, et al. Sunscreen use, wearing clothes, and number of nevi in 6- to 7-year-old European children. J Natl Cancer Inst 1998; 90: 1873–1880.
13. Ahmed S, Lutalo T, Wawer M, Serwadda D, Sewankambo NK, Nalugoda F, et al. HIV incidence and sexually transmitted disease prevalence associated with condom use: a population study in Rakai, Uganda. AIDS 2001; 15: 2171–2179.
14. Kajubi P, Kamya M, Kamya S, Chen S, McFarland W, Hearst N. Increasing condom use without reducing HIV risk: results of a controlled community trial in Uganda. J Acquir Immune Defic Syndr 2005; 40: 77–82.
15. Halperin DT, Steiner M, Cassell MM, Green EC, Hearst N, Kirby D, et al. The time has come for common ground on preventing sexual transmission of HIV. Lancet 2004; 364: 1913–1915.
16. Stolte IG, Dukers NHTM, Geskus RB, Coutinho RA, de Wit JBF. Homosexual men change to risky sex when perceiving less threat of HIV/AIDS since availability of highly active antiretroviral therapy: a longitudinal study. AIDS 2004; 18: 303–309.
17. Tun W, Celentano DD, Vlahov D, Strathdee SA. Attitudes toward HIV treatments influence unsafe sexual and injection practices among injecting drug users. AIDS 2003; 17: 1953–1962.
18. Grémy I, Beltzer N. HIV risk and condom use in the adult heterosexual population in France between 1992 and 2001: return to the starting point? AIDS 2004; 18: 805–809.
19. Crepaz N, Hart TA, Marks G. Highly active antiretroviral therapy and sexual risk behavior: a meta-analytic review. JAMA 2004; 292: 224–236.
20. Costello D. AIDS pill tenofovir as party drug? Los Angeles Times 2005 Dec 19.
21. UK Collaborative Group on Monitoring the Transmission of HIV Drug Resistance. Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. BMJ 2001; 322: 1087–1088.
22. Glanz K, Rimer BK, Lewis FM eds. Health behavior and health education: theory, research and practice. 3rd ed. San Francisco, CA: Jossey-Bass, 2002.
23. Stoneburner R, Low-Beer D. Population-level HIV declines and behavioral risk avoidance in Uganda. Science 2004; 304: 714–718.
24. Shelton JD, Halperin D, Nantulya V, Potts M, Gayle HD, Holmes KK. Partner reduction is crucial for balanced “ABC” approach to HIV prevention. BMJ 2004; 328: 891–893.